CCBIO Seminar - Ole Frithjof Norheim
CCBIO Seminar with speaker Ole Frithjof Norheim, physician and professor in medical ethics at the Department of Global Public Health and Primary Care, University of Bergen, and adjunct professor at the Department of Global Health and Population, Harvard TH Chan School of Public Health.
Hovedinnhold
Welcome to the CCBIO Seminar series!
Time: Thursday February 22nd 2018, at 14.30.
Place: Auditorium 4, BB-building, Jonas Lies vei 91, Bergen.
Speaker: Ole Frithjof Norheim, physician and professor in medical ethics at the Department of Global Public Health and Primary Care, University of Bergen, and adjunct professor at the Department of Global Health and Population, Harvard TH Chan School of Public Health. Norheim is also a CCBIO associate investigator.
Title: "Can biomarkers improve priority setting for new, expensive cancer drugs?"
Abstract:
This talk will discuss how reimbursement decisions for new expensive cancer drugs are made in Norway and UK. Cost-effectiveness and severity of disease are two important criteria. These can vary significantly by patient heterogeneity in prognosis and treatment effect. Adjuvant Trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive breast cancer is used as a model for discussion of subgroup analysis with respect to priority setting and costeffectiveness thresholds. Implications for newer drugs will also be discussed.
Chairperson: Roger Strand
All interested researchers, students and others are welcome!